Drugs that contain Sacubitril; Valsartan

1. List of Entresto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877938 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8404744 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2023

(16 days ago)

US8796331 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2023

(16 days ago)

US8404744

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2023

(5 months from now)

US8796331

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2023

(5 months from now)

US7468390 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Nov, 2023

(9 months from now)

US7468390

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
May, 2024

(1 year, 3 months from now)

US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2025

(1 year, 11 months from now)

US8101659

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2025

(2 years from now)

US9388134 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2026

(3 years from now)

US9388134

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(4 years from now)

US8877938

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2027

(4 years from now)

US9937143 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(10 years from now)

US9517226 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(10 years from now)

US11135192 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(10 years from now)

US11058667 NOVARTIS PHARMS CORP Sacubitril-valsartan dosage regimen for treating heart failure
May, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Oct 1, 2022
M Feb 16, 2024
Pediatric Exclusivity (PED) Apr 1, 2023

Market Authorisation Date: 07 July, 2015

Treatment: Treatment of heart failure; Treatment of heart failure with preserved ejection fraction; Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually recommended starting dose

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic